Bupranolol

From Self-sufficiency
Jump to: navigation, search
Bupranolol
File:Bupranolol.svg
Systematic (IUPAC) name
(RS)-1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
Clinical data
Routes of
administration
Oral, topical (eye drops)
Pharmacokinetic data
Bioavailability < 10%
Protein binding 76%
Metabolism First pass elimination > 90%
Biological half-life 2-4 hours (plasma)
Excretion > 88% renal (as carboxybupranolol)
Identifiers
CAS Number 23284-25-5
ATC code C07AA19 (WHO)
PubChem CID 2475
IUPHAR/BPS 550
Chemical data
Formula C14H22ClNO2
Molar mass 271.78298 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and dosage

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0,05%-0,5%) are used against glaucoma.

Pharmacology

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid, of which 88% are eliminated renally within 24 hours.

Adverse effects, contraindications, interactions

Adverse effects, contraindications and interactions are similar to other beta blockers.

References

Dinnendahl, V, Fricke, U, ed. (2007). Arzneistoff-Profile (in German). 2 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-98-46-3. 

es:Bupranolol